Ultra-Processed Food Policy Demands Escalate as Researchers Cite Systemic Issues
Decision brief
Answer first · skim in under a minute
Leading researchers are issuing a strong call for comprehensive policy reforms to combat the global health crisis linked to ultra-processed foods. They argue that the current system is inherently biased, necessitating urgent governmental and public health interventions.
Ultra-processed food policy is moving from academic debate into federal rulemaking. The FDA and USDA opened a 2025 Request for Information to define ultra-processed foods, while cohort data continue to link high intake with type 2 diabetes risk that underpins metabolic drug demand.
Contents10 sections
Key Takeaways
- FDA and USDA issued a joint ultra-processed foods RFI on July 24, 2025, and extended comments to October 23 while seeking a uniform federal definition.
- Congressional Research Service notes that U.S. statute still lacks a legal definition of ultra-processed food, even as NOVA remains the dominant research taxonomy.
- A prospective cohort found highest-quartile ultra-processed intake (about 8.4 servings/day) associated with a diabetes hazard ratio of 1.13 over 21 years of follow-up.
- Pharma metabolic franchises should model dual scenarios: near-term obesity and diabetes demand versus longer-term prevention pressure if labeling, marketing, or formulation rules tighten.
Why is ultra-processed food policy accelerating now?
Federal agencies frame diet-related chronic disease — including type 2 diabetes, obesity, and cardiovascular disease — as a public health and economic priority. On its ultra-processed foods page, the U.S. Food and Drug Administration describes a joint FDA–USDA effort to gather criteria for a uniform definition, calling that step foundational for consistent research and policy.
In May 2025, FDA also announced a partnership with the National Institutes of Health on a Nutrition Regulatory Science Program that includes questions about how ultra-processed food consumption may affect health. That sequence — science workshop in December 2024, NIH partnership in May 2025, RFI in July 2025 — marks a clear shift from commentary to administrative process.
What did the FDA–USDA RFI actually request?
The July 24, 2025 Request for Information asked stakeholders what factors should enter a federal ultra-processed foods definition. FDA later said the agencies extended the comment window by 30 days, to October 23, to collect more data. The agency explicitly ties the definition work to enabling consistent policies and programs once criteria exist.
That is narrower than some advocacy narratives. The RFI does not, by itself, impose a sugary-drink tax, additive ban, or marketing restriction. It is a definitional precursor. For industry counsel and BD teams, the practical signal is that labeling, school-food, and procurement standards become easier to write once a shared federal vocabulary exists.
How does NOVA fit — and where does it fall short?
Researchers commonly use the NOVA system, which places industrially formulated products with cosmetic additives into group 4 (“ultra-processed”). A Congressional Research Service brief on ultra-processed foods states that U.S. law and regulation still do not define the term, while summarizing how FDA labeling rules already disclose ingredients such as added sugars, hydrogenated oils, flavors, colors, and emulsifiers.
- NOVA group 4 emphasizes industrial formulations and additives rarely used in home kitchens.
- CRS notes policy interest in labeling, marketing, and production of highly processed products.
- Without a U.S. statutory definition, state and federal measures risk inconsistent thresholds and legal challenge.
What does the diabetes evidence show?
Policy pressure rests partly on epidemiology. In a population-based prospective cohort published via PMC, investigators followed participants for a median 21 years and recorded 4,539 incident diabetes cases. People in the highest ultra-processed food intake quartile averaged 8.4 servings per day and had a hazard ratio of 1.13 (95% CI 1.03–1.23) versus the lowest quartile after sociodemographic, lifestyle, and clinical adjustment.
Each additional daily serving was associated with about a 2% higher diabetes risk (HR 1.02). Subgroup patterns pointed to sugar- and artificially sweetened beverages, ultra-processed meats, and sugary snacks. Adjustment for body mass index attenuated the association, consistent with weight gain as a mediating pathway — relevant for companies selling GLP-1 and other anti-obesity agents.
What does this mean for pharmaceutical strategy?
If ultra-processed food policy eventually reduces population exposure through labeling, reformulation, or procurement rules, long-run incidence of diet-related disease could soften. Near term, the opposite commercial reality persists: high ultra-processed intake and obesity prevalence sustain demand for diabetes and obesity therapies. Scenario planning should therefore separate 2025–2027 demand from 2030-plus prevention effects rather than treating “policy” as an immediate volume cliff.
Food manufacturers face a clearer operational risk: definitional clarity enables targeted standards. Pharma does not reformulate grocery SKUs, but it does compete for payer attention in the same chronic-disease budget. Prevention narratives that cite ultra-processed food policy can influence medical-affairs messaging and health-economics models.
What remains unproven for regulators?
FDA itself states that many questions remain about how and why ultra-processed foods may harm health, which is why the Nutrition Regulatory Science Program and the RFI exist. Cohort associations are not the same as a causal regulatory standard. Dose–response thresholds, subgroup heterogeneity, and the relative role of additives versus nutrient profile are still contested. Claims that a single tax or additive ban will rapidly reverse diabetes prevalence are not established by the federal materials cited here.
Related NovaPharma coverage
- Obesity rates in America by year: what the data shows
- Chile warning labels on food: new evidence on efficacy and obesity risk
- AstraZeneca expands obesity push with $125M ultrasound medicine investment
Frequently Asked Questions
What is the FDA doing on ultra-processed food policy?
On July 24, 2025, FDA and USDA issued a joint Request for Information to help build a uniform U.S. definition of ultra-processed foods, later extending the comment period to October 23.
Why does NOVA matter for regulators?
NOVA is the most common research framework for classifying ultra-processed foods, but it is not a U.S. statutory definition, so federal agencies are seeking criteria that can support consistent labeling and policy.
How does ultra-processed food intake relate to diabetes risk?
In a prospective cohort with 21 years of follow-up and 4,539 incident diabetes cases, people in the highest ultra-processed food intake quartile averaged 8.4 servings per day and had a higher diabetes hazard ratio of 1.13 versus the lowest quartile.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
